ArriVent BioPharma, Inc. (AVBP)
| Market Cap | 1.43B +104.8% |
| Revenue (ttm) | n/a |
| Net Income | -145.24M |
| EPS | -3.52 |
| Shares Out | 46.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 214,998 |
| Open | 30.79 |
| Previous Close | 30.84 |
| Day's Range | 30.25 - 31.15 |
| 52-Week Range | 16.10 - 35.83 |
| Beta | 1.37 |
| Analysts | Strong Buy |
| Price Target | 44.60 (+44.81%) |
| Earnings Date | Aug 12, 2026 |
About AVBP
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for AVBP stock is "Strong Buy." The 12-month stock price target is $44.6, which is an increase of 44.81% from the latest price.
News
ArriVent BioPharma Transcript: AGM 2026
The meeting confirmed a quorum and proceeded virtually, electing three directors for terms ending in 2029 and ratifying PricewaterhouseCoopers LLP as auditor for 2026. No questions were received from stockholders during the Q&A session.
ArriVent Biopharma assumed with a Buy at Truist
Truist assumed coverage of ArriVent Biopharma (AVBP) with a Buy rating with a price target of $45, up from $43. The firm views the company’s firmo – firmonertinib – as…
ArriVent Biopharma price target lowered to $43 from $45 at Citi
Citi lowered the firm’s price target on ArriVent Biopharma (AVBP) to $43 from $45 and keeps a Buy rating on the shares.
ArriVent Biopharma reports Q1 EPS (96c), consensus (89c)
“Our two ongoing pivotal firmonertinib trials in uncommon EGFR-mutant non-small cell lung cancer continue to advance, with topline monotherapy data for frontline EGFR exon 20 insertion mutations expec...
ArriVent BioPharma Reports First Quarter 2026 Financial Results
NEWTOWN SQUARE, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innova...
ArriVent BioPharma Earnings release: Q1 2026
ArriVent BioPharma released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
ArriVent BioPharma Quarterly report: Q1 2026
ArriVent BioPharma has published its Q1 2026 quarterly earnings report on May 11, 2026.
ArriVent BioPharma Slides: Corporate presentation
ArriVent BioPharma has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
ArriVent Biopharma announces FDA clearance of ARR-002 NDA
ArriVent BioPharma (AVBP) announced clearance of an investigational new drug application by the FDA for ARR-002, a MUC16/NaPi2b targeting tetravalent antibody-drug conjugate with an initial focus in o...
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
NEWTOWN SQUARE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innova...
ArriVent BioPharma Proxy statement: Proxy filing
ArriVent BioPharma filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
ArriVent BioPharma Proxy statement: Proxy filing
ArriVent BioPharma filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Citi ups ArriVent target, opens ‘upside 90-day catalyst watch’
Citi raised the firm’s price target on ArriVent Biopharma (AVBP) to $45 from $33 and keeps a Buy rating on the shares. The firm expects the company to announce positive…
ArriVent Biopharma price target raised to $45 from $37 at B. Riley
B. Riley raised the firm’s price target on ArriVent Biopharma (AVBP) to $45 from $37 and keeps a Buy rating on the shares. Following Dizal’s positive Phase 3 WU-KONG28 results…
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
NEWTOWN SQUARE, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of inno...
ArriVent Biopharma assumed with a Buy at BTIG
BTIG analyst Jeet Mukherjee assumed coverage of ArriVent Biopharma (AVBP) with a Buy rating and $42 price target The firm says its Bay call is anchored by the FURVENT phase…
ArriVent Biopharma price target raised to $50 from $44 at Oppenheimer
Oppenheimer analyst Jeff Jones raised the firm’s price target on ArriVent Biopharma (AVBP) to $50 from $44 and keeps an Outperform rating on the shares. The firm notes that Thursday…
ArriVent Biopharma price target raised to $44 from $42 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on ArriVent Biopharma (AVBP) to $44 from $42 and keeps a Buy rating on the shares. The firm reiterates ArriVent…
ArriVent Biopharma price target raised to $33 from $31 at Citi
Citi raised the firm’s price target on ArriVent Biopharma (AVBP) to $33 from $31 and keeps a Buy rating on the shares. The firm updated the company’s model post the…
ArriVent BioPharma Reports Full Year 2025 Financial Results
NEWTOWN SQUARE, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of inno...
ArriVent BioPharma Annual report: Q4 2025
ArriVent BioPharma has published its Q4 2025 annual report on March 5, 2026.
ArriVent BioPharma Earnings release: Q4 2025
ArriVent BioPharma released its Q4 2025 earnings on March 5, 2026, summarizing the period's financial results.
Omega takes new stake in Rocket Companies, exits ArriVent Biopharma
Leon Cooperman’s Omega Advisors disclosed in an SEC filing its holdings as of December 31, 2025. Omega’s one new buy during the fourth quarter was Rocket Companies (RKT). Omega exited…
ArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of ArriVent Biopharma (AVBP) with an Overweight rating. Firmonertinib is approved in China for first-line non-small cell lung cancer with classical EGFR mutations,...
ArriVent Biopharma announces first patient dosed in Phase 3 ALPACCA study
ArriVent BioPharma (AVBP) announced that the first patient has been dosed in the global pivotal Phase 3 ALPACCA study evaluating firmonertinib monotherapy for first-line treatment of EGFR PACC mutant ...